

# Benjamin Y Kong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1753541/publications.pdf>

Version: 2024-02-01

18  
papers

2,073  
citations

623734

14  
h-index

839539

18  
g-index

18  
all docs

18  
docs citations

18  
times ranked

3879  
citing authors

#	ARTICLE	IF	CITATIONS
1	LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided Therapies at relapse: Protocol for a pilot study. <i>BMJ Open</i> , 2021, 11, e054075.	1.9	2
2	On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2019, 9, 50.	2.8	11
3	Dendritic cells as cancer therapeutics. <i>Seminars in Cell and Developmental Biology</i> , 2019, 86, 77-88.	5.0	50
4	A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission. <i>Oncolmmunology</i> , 2018, 7, e1419114.	4.6	24
5	Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. <i>Clinical Cancer Research</i> , 2017, 23, 5024-5033.	7.0	192
6	Reply to "Comment on "Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy". <i>British Journal of Cancer</i> , 2017, 116, e15-e15.	6.4	1
7	Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. <i>Lancet Oncology</i> , The, 2017, 18, 1202-1210.	10.7	211
8	Pneumonitis in Patients Treated With Anti"Programmed Death-1/Programmed Death Ligand 1 Therapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 709-717.	1.6	829
9	Acute Truncal Lymphedema Secondary to Axillary Metastatic Melanoma Presenting Like Cellulitis. <i>Case Reports in Medicine</i> , 2017, 2017, 1-3.	0.7	2
10	Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. <i>Melanoma Research</i> , 2016, 26, 202-204.	1.2	92
11	Residual <sup>18</sup> F-FDG PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 572-577.	3.3	81
12	Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. <i>British Journal of Cancer</i> , 2016, 114, 1084-1089.	6.4	113
13	Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. <i>Oncolmmunology</i> , 2016, 5, e1214788.	4.6	123
14	Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 455-461.e1.	1.2	247
15	Allosteric Effect of ATP on Na <sup>+</sup> ,K <sup>+</sup> -ATPase Conformational Kinetics. <i>Biochemistry</i> , 2007, 46, 7034-7044.	2.5	35
16	Dietary cholesterol alters Na <sup>+</sup> /K <sup>+</sup> selectivity at intracellular Na <sup>+</sup> /K <sup>+</sup> pump sites in cardiac myocytes. <i>American Journal of Physiology - Cell Physiology</i> , 2004, 286, C398-C405.	4.6	20
17	Identification of Potential Regulatory Sites of the Na <sup>+</sup> ,K <sup>+</sup> -ATPase by Kinetic Analysis. <i>Biochemistry</i> , 2004, 43, 2241-2250.	2.5	22
18	Dependence of Na <sup>+</sup> -K <sup>+</sup> pump current-voltage relationship on intracellular Na <sup>+</sup> , K <sup>+</sup> , and Cs <sup>+</sup> in rabbit cardiac myocytes. <i>American Journal of Physiology - Cell Physiology</i> , 2002, 283, C1511-C1521.	4.6	18